RabAvert Rabies Vaccine
Rabies prevention with RabAvert rabies vaccine
RabAvert vaccine, rabies vaccine available for both preexposure immunization and postexposure prophylaxis, is included in the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations for human rabies prevention1:
The Novartis rabies vaccines are the world’s most widely distributed cell culture rabies vaccines3
- Preexposure vaccination
- Booster immunization
- Postexposure treatment (PET)
- More than 55 million doses distributed worldwide since 1985
- Market leader in Europe and other regions worldwide
Important safety information
Anaphylaxis, encephalitis including death, meningitis, neuroparalytic events such as encephalitis, transient paralysis, Guillain-Barré syndrome, myelitis, and retrobulbar neuritis; and multiple sclerosis have been reported to be temporally associated with the use of RabAvert vaccine.
The most commonly occurring adverse reactions are injection site reactions, such as injection site erythema, induration and pain; flu-like symptoms; arthralgia; dizziness; lymphadenopathy; nausea; and rash.
History of anaphylaxis to the vaccine or any of the vaccine components constitutes a contraindication to preexposure vaccination with this vaccine. In the case of postexposure prophylaxis, if an alternative product is not available, vaccination should proceed with caution and close observation. A patient’s risk of acquiring rabies must be carefully considered before discontinuing vaccination.
1. Centers for Disease Control and Prevention. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008;57(RR-3):1-28. 2. World Health Organization. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec. 2007;82(49-50):425-436. 3. Data on file. Novartis Vaccines & Diagnostics, Inc.